Plasma cell myeloma and leukemia.
Wiernik
Peter H
PH
Our Lady of Mercy Cancer Center, New York Medical College, Bronx 10466, USA. Pwiernik@aol.com
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D002648:Child; D002986:Clinical Trials as Topic; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D000068877:Imatinib Mesylate; D007938:Leukemia / Q000276:immunology / Q000473:pathology / Q000503:physiopathology* / Q000628:therapy; D009101:Multiple Myeloma / Q000276:immunology / Q000473:pathology / Q000503:physiopathology* / Q000628:therapy; D010879:Piperazines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use
D000970:Antineoplastic Agents; D001549:Benzamides; D004791:Enzyme Inhibitors; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate